Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Keywords: 
CAR T cell therapy
Idecabtagene vicleucel
Patient experience
Patient-reported outcomes
Relapsed or refractory multiple myeloma
Triple-class exposed
Issue Date: 
2023
ISSN: 
0145-2126
Note: 
This is an open access article under the CC BY-NC-ND license
Citation: 
Delforge, M.; Rodríguez-Otero, P. (Paula); Shah, N.; et al. "Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial". Leukemia Research. 129, 2023, 107074
Abstract
Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial.Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored patient perceptions of ide-cel treatment experience, advantages and disadvantages, and long-term health-related quality of life impact. Patient journeys were developed from narrative analysis of perceived treatment benefits with known remission length.Results: Interviews with 45 patients 6-24 months postinfusion were analyzed; all reported >= 1 ide-cel treatment advantage, most often related to efficacy (n = 42/45, 93%), few or no side effects (n = 35/45, 78%), and avoidance of other treatments (n = 34/45, 76%). Patients generally reported 6-month improvements in physical health, functioning, emotional well-being, social life, and outlook on the future; these improvements mostly remained stable through 18 and 24 months. The most common patient journeys comprised physical, func-tioning, or emotional benefit with remission < 2 years.Conclusions: Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment.Trial Registration Number and Date: NCT03361748. December 5, 2017.

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
3.65 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.